InvestSMART

MGC Pharmaceuticals Ltd (ASX: MXC) - Announcements

Current share price for MXC : $0.420 0.01 (2.44%)+

ASX company news and announcements for MGC Pharmaceuticals Ltd (MXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All MGC Pharmaceuticals Ltd (MXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than MGC Pharmaceuticals Ltd (MXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for MGC Pharmaceuticals Ltd (MXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Brazil Distribution Agreement signed for MGC Pharma Products 19 Jun 2019 9:44AM $0.051 $0.420 risen by 723.53%
$18 Pharma Update - Increased Orders and Clinical Study 13 Jun 2019 9:37AM $0.051 $0.420 risen by 723.53%
$18 Digital Platform for MGC Pharma's ILC with RMIT 7 Jun 2019 9:46AM $0.052 $0.420 risen by 707.69%
$18 Material Revenues Confirmed from Non-Pharma Business Units 4 Jun 2019 9:53AM $0.052 $0.420 risen by 707.69%
$18 Trading Halt 3 Jun 2019 9:34AM $0.052 $0.420 risen by 707.69%
$18 Upcoming Expiry of Listed Options MXCOD 31 May 2019 4:00PM $0.053 $0.420 risen by 692.45%
$18 Cultivation Licence Granted by the Office of Drug Control 29 May 2019 9:20AM $0.053 $0.420 risen by 692.45%
$18 Research - the Effectiveness of Cannabinoids on Glioblastoma 24 May 2019 9:38AM $0.059 $0.420 risen by 611.86%
$18 Company Presentation- Canaccord Cannabis Conference 2019 NYC 15 May 2019 9:37AM $0.060 $0.420 risen by 600%
$18 Arrival of First CannEpil Shipment to United Kingdom 7 May 2019 9:10AM $0.050 $0.420 risen by 740%
$18 UK Distribution Agreement with Grow Biotech and IPS 6 May 2019 8:56AM $0.050 $0.420 risen by 740%
$18 New Distribution Agreements Signed for CannEpil & IMP's 2 May 2019 9:36AM $0.042 $0.420 risen by 900%
$18 March Quarterly Activity and Cashflow Report 30 Apr 2019 1:37PM $0.048 $0.420 risen by 775%
$18 Agreement for CBD Nutraceuticals Entry into China Market 17 Apr 2019 11:27AM $0.041 $0.420 risen by 924.39%
$18 Updated CannEpil First Purchase Orders & UK Permit Approval 16 Apr 2019 10:43AM $0.040 $0.420 risen by 950%
$18 Issue of Unlisted Options - Appendix 3B 12 Apr 2019 6:22PM $0.043 $0.420 risen by 876.74%
$18 Received CannEpil Purchase Orders and Import Permit for UK 12 Apr 2019 9:27AM $0.035 $0.420 risen by 1,100%
$18 MXC's 2019 Pharma Commercialisation Strategy 2 Apr 2019 9:28AM $0.034 $0.420 risen by 1,135.29%
$18 CannaTech Conference Presentation - Tel Aviv 2019 1 Apr 2019 9:17AM $0.035 $0.420 risen by 1,100%
$18 Initial Director's Interest Notice Appx 3X Dr Stephen Parker 13 Mar 2019 9:41AM $0.037 $0.420 risen by 1,035.14%
$18 European Corporate and Pharma Industry Expert Appointed NED 13 Mar 2019 9:35AM $0.037 $0.420 risen by 1,035.14%
$18 Half Yearly Report and Accounts 28 Feb 2019 7:19PM $0.039 $0.420 risen by 976.92%
$18 Resignation of Joint Company Secretary 28 Feb 2019 6:51PM $0.039 $0.420 risen by 976.92%
$18 Independent Validation of MXC High-Grade Cannabis Genetics 26 Feb 2019 9:33AM $0.040 $0.420 risen by 950%
$18 Change of Director's Interest Notice- Appx 3Y Roby Zomer 25 Feb 2019 2:10PM $0.039 $0.420 risen by 976.92%

551 - 575 of 818 results

Page 23 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.